| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2014) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | L01ED02 |
| UNII: | K418KG2GET |
| InChI Key | VERWOWGGCGHDQE-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C28H36ClN5O3S |
| Molecular Weight | 558.15 |
| AlogP | 6.36 |
| Hydrogen Bond Acceptor | 8.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 9.0 |
| Polar Surface Area | 105.24 |
| Molecular species | BASE |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 38.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | ALK tyrosine kinase receptor inhibitor | FDA |
| Primary Target | |
|---|---|
| ALK receptor tyrosine kinase |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | 4 | D002289 | ClinicalTrials |
| Neoplasms | 4 | D009369 | ClinicalTrials |
| Sarcoma | 3 | D012509 | ClinicalTrials |
| Neuroblastoma | 2 | D009447 | ClinicalTrials |
| Melanoma | 2 | D008545 | ClinicalTrials |
| Cholangiocarcinoma | 2 | D018281 | ClinicalTrials |
| Thyroid Neoplasms | 2 | D013964 | ClinicalTrials |
| Granuloma, Plasma Cell | 2 | D006104 | ClinicalTrials |
| Lymphoma, Large-Cell, Anaplastic | 2 | D017728 | ClinicalTrials |
| Melanoma | 2 | D008545 | ClinicalTrials |
| Glioblastoma | 2 | D005909 | ClinicalTrials |
| Liver Diseases | 1 | D008107 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 1032900-25-6 |
| ChEBI | 78432 |
| ChEMBL | CHEMBL2403108 |
| DrugBank | DB09063 |
| DrugCentral | 4866 |
| EPA CompTox | DTXSID10725373 |
| FDA SRS | K418KG2GET |
| Guide to Pharmacology | 7397 |
| PDB | 4MK |
| PubChem | 57379345 |
| SureChEMBL | SCHEMBL1014329 |
| ZINC | ZINC000096272772 |